How McK­in­sey used its FDA con­nec­tions to help opi­oid man­u­fac­tur­ers: New con­gres­sion­al re­port

Fol­low­ing re­ports that McK­in­sey en­gaged in abu­sive and de­cep­tive busi­ness prac­tices to stoke the flames of the opi­oid epi­dem­ic, the House Over­sight Com­mit­tee on Wednes­day re­leased a new re­port doc­u­ment­ing how the con­sult­ing com­pa­ny lever­aged its work with the FDA to dri­ve new busi­ness with opi­oid man­u­fac­tur­ers.

Doc­u­ments un­cov­ered by the com­mit­tee al­so show how opi­oid jug­ger­naut Pur­due Phar­ma ex­plic­it­ly tasked McK­in­sey with pro­vid­ing ad­vice on how to in­flu­ence the FDA’s de­ci­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.